Promising Data for LOXO-292 in Thyroid Cancers
Lori J. Wirth, MD, discusses the promising results seen so far with LOXO-292 in patients with thyroid cancer.
Lori J. Wirth, MD, associate professor of medicine at Harvard Medical School and medical director of the Center for Head and Neck Cancers at Massachusetts General Hospital, discusses the promising results seen so far with LOXO-292 in patients with thyroid cancer.
LOXO-292 has been well-tolerated so far with few significant adverse events (AEs). Most AEs have only been grade 1 and grade 2. The recommended dose found in the dose escalation trial is now being moved to an expansion cohort.
For patients withRET-fusion tumors in patients with nonsmall cell lung cancer and differentiated thyroid cancer, the response rate has been around 77%, while patients withRET
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
Anticipating Novel Options for the RAI-Refractory DTC Armamentarium
May 15th 2023In season 4, episode 6 of Targeted Talks, Warren Swegal, MD, takes a multidisciplinary look at the RAI-refractory differentiated thyroid cancer treatment landscape, including the research behind 2 promising systemic therapy options.
Listen
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
Post Hoc and Real-World Analyses Explore Benefit of Lenvatinib in DTC
December 5th 2024During a Case-Based Roundtable® event, Lori J. Wirth, discussed recent analyses that have developed a better understanding of the outcomes with lenvatinib in differentiated thyroid cancer in the second article of a 2-part series.
Read More
